Safety and Efficacy of Early Vitamin D Supplementation in Critically Ill Extremely Preterm Infants: An Ancillary Study of a Randomized Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Per-protocol analysis using unadjusted, repeated-measures mixed models.

Who Took Part

By PubMed's age tags, the people studied were infants, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Ancillary study of a masked randomized clinical trial.

What Was Measured

Per-protocol analysis using unadjusted, repeated-measures mixed models.

Topics PubMed links to this paper include Infant, Extremely Premature, Bronchopulmonary Dysplasia, Critical Illness, Calcium, Dietary Supplements, Vitamins and Vitamin D Deficiency.

The authors tagged it with the keywords Cholecalciferol, Chronic lung disease, Neonates, Premature newborn and Racial disparities.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Journal of the Academy of Nutrition and Dietetics), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.